Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Point72 Asia Singapore Pte. Ltd. grew its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 281.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,504 shares of the company’s stock after purchasing an additional 29,159 shares during the period. Point72 Asia Singapore Pte. Ltd. owned about 0.13% of Dianthus Therapeutics worth $1,022,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics during the second quarter valued at $112,000. WINTON GROUP Ltd purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at $265,000. Point72 DIFC Ltd purchased a new stake in Dianthus Therapeutics during the second quarter valued at $334,000. Virtu Financial LLC bought a new position in Dianthus Therapeutics in the first quarter valued at about $390,000. Finally, Hussman Strategic Advisors Inc. purchased a new position in Dianthus Therapeutics in the first quarter worth about $630,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $27.85 on Wednesday. The business’s 50-day simple moving average is $27.91 and its two-hundred day simple moving average is $26.19. Dianthus Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The business had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on DNTH. Wedbush lowered their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an “outperform” rating and a $58.00 price objective for the company. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They issued an “overweight” rating on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Monday, August 12th. Finally, Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $44.71.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.